Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin

Br J Nutr. 2013 Jul 28;110(2):197-205. doi: 10.1017/S0007114512004850. Epub 2012 Dec 5.

Abstract

The objective of the present study was to evaluate anti-diabetic effects of chromium picolinate (CrPic) and biotin supplementations in type 2 diabetic rats. The type 2 diabetic rat model was induced by high-fat diet (HFD) and low-dose streptozotocin. The rats were divided into five groups as follows: (1) non-diabetic rats fed a regular diet; (2) diabetic rats fed a HFD; (3) diabetic rats fed a HFD and supplemented with CrPic (80 μg/kg body weight (BW) per d); (4) diabetic rats fed a HFD and supplemented with biotin (300 μg/kg BW per d); (5) diabetic rats fed a HFD and supplemented with both CrPic and biotin. Circulating glucose, cortisol, total cholesterol, TAG, NEFA and malondialdehyde concentrations decreased (P< 0·05), but serum insulin concentrations increased (P< 0·05) in diabetic rats treated with biotin and CrPic, particularly with a combination of the supplements. Feeding a HFD to diabetic rats decreased PPAR-γ expression in adipose tissue and phosphorylated insulin receptor substrate 1 (p-IRS-1) expression of liver, kidney and muscle tissues, while the supplements increased (P< 0·001) PPAR-γ and p-IRS-1 expressions in relevant tissues. Expression of NF-κB in the liver and kidney was greater in diabetic rats fed a HFD, as compared with rats fed a regular diet (P< 0·01). The supplements decreased the expression of NF-κB in diabetic rats (P< 0·05). Results of the present study revealed that supplementing CrPic and biotin alone or in a combination exerts anti-diabetic activities, probably through modulation of PPAR-γ, IRS-1 and NF-κB proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism
  • Animals
  • Biotin / pharmacology
  • Biotin / therapeutic use*
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / etiology
  • Diabetes Mellitus, Experimental / metabolism
  • Diet, High-Fat / adverse effects*
  • Dietary Supplements*
  • Hydrocortisone / blood
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Insulin Receptor Substrate Proteins / metabolism
  • Kidney / metabolism
  • Lipids / blood
  • Liver / metabolism
  • Male
  • Malondialdehyde / blood
  • Micronutrients / pharmacology
  • Micronutrients / therapeutic use*
  • Muscles / metabolism
  • NF-kappa B / metabolism
  • PPAR gamma / metabolism
  • Picolinic Acids / pharmacology
  • Picolinic Acids / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Streptozocin

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Irs1 protein, rat
  • Lipids
  • Micronutrients
  • NF-kappa B
  • PPAR gamma
  • Picolinic Acids
  • Malondialdehyde
  • Streptozocin
  • Biotin
  • picolinic acid
  • Hydrocortisone